drugset / Trial / NCT00985543
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval, following administration to male and female HIV-negative healthy volunteers of: 1. Lopinavir/ritonavir 400/100 mg twice daily 2. Lopinavir/ritonavir 200/150 mg twice daily 3. Lopinavir/ritonavir 200/50 mg twice daily
Timeline
- Start
- 2009-10
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lopinavir | Other / unclassified | 200 mg | — |
| Subject | Lopinavir | Other / unclassified | 400 mg | — |
| Subject | Ritonavir | Other / unclassified | 50 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | Ritonavir | Other / unclassified | 150 mg | — |